RegWardenFDA facility compliance records
Facility

INFINIUM MEDICAL, INC.

1 recall(s) on record — most severe on record: Class II.

Activity by year

FDA actions on record by year2019: 1 recalls, 1 inspections; 2023: 1 inspections201720182201920202021202212023202420252026
  • Recalls (1)
  • Inspections (2)

Devices registered here (1)

  • Monitor, Physiological, Patient (Without Arrhythmia Detection Or Alarms)
    Product code MWI (opens in a new tab) · Class II · Cardiovascular · 21 CFR 870.2300

Recalls & enforcement

  • Class IIOngoing2019-05-31
    The CLEO & Tranquility VS Patient Monitors 510(k) indications for use in the United States did not include the temperature monitor accessory option.

FDA inspections (2)

  • VAI2023-11-08
    Voluntary Action Indicated · Compliance: Devices; Postmarket Assurance: Devices · citations posted
  • VAI2019-05-15
    Voluntary Action Indicated · Compliance: Devices; Postmarket Assurance: Devices · citations posted

Source: U.S. FDA Inspections Dashboard (opens in a new tab) (device inspection classifications, 2016–present). Data as of 2026-10-06. The dashboard profile can take several seconds to load.

Related

Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this facility record at FDA → (opens in a new tab)

Cite this record

RegWarden. “INFINIUM MEDICAL, INC. (FEI 3007513035) — FDA facility record.” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/facility/3007513035-infinium-medical-inc/

Not open yet

Alerts for INFINIUM MEDICAL, INC.

Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.

Planned

Want a one-page facility brief?

A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.